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PTEN mediates Notch-dependent stalk cell
arrest in angiogenesis
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Anna Bigas11, Arkaitz Carracedo2,12,13, Holger Gerhardt3,14 & Mariona Graupera1
Coordinated activity of VEGF and Notch signals guides the endothelial cell (EC) speciﬁcation
into tip and stalk cells during angiogenesis. Notch activation in stalk cells leads to proliferation
arrest via an unknown mechanism. By using gain- and loss-of-function gene-targeting
approaches, here we show that PTEN is crucial for blocking stalk cell proliferation down-
stream of Notch, and this is critical for mouse vessel development. Endothelial deletion of
PTEN results in vascular hyperplasia due to a failure to mediate Notch-induced proliferation
arrest. Conversely, overexpression of PTEN reduces vascular density and abrogates the
increase in EC proliferation induced by Notch blockade. PTEN is a lipid/protein phosphatase
that also has nuclear phosphatase-independent functions. We show that both the catalytic
and non-catalytic APC/C-Fzr1/Cdh1-mediated activities of PTEN are required for stalk cells’
proliferative arrest. These ﬁndings deﬁne a Notch–PTEN signalling axis as an orchestrator of
vessel density and implicate the PTEN-APC/C-Fzr1/Cdh1 hub in angiogenesis.
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V
essel sprouting is a central mechanism of blood vessel
growth1,2 and it relies on the induction of specialized
endothelial cell (EC) populations, each accounting for
distinct functions. At the very front of the sprouts, tip cells
provide guidance and migrate towards gradients of vascular
endothelial growth factor (VEGF)-A, but rarely proliferate2–4.
Instead, trailing stalk cells located at the base of the sprout
proliferate, establish adherent and tight junctions and form the
vascular lumen1,2,5.
The tip cell phenotype is usually associated with high levels of
Delta-like 4 (Dll4), which activate Notch in neighbouring stalk
cells, preventing them from becoming a new tip cell. Notch
signalling is initiated by receptor–ligand recognition between
adjacent cells. This interaction results in two sequential
proteolytic events that release the Notch intracellular domain
(NICD). Subsequently, NICD translocates to the nucleus, where it
forms a complex with the transcriptional factor Rbpj/Cbf1 and
the Mastermind-like proteins to drive target gene expression6,7.
Activation of Notch in ECs leads to cell cycle arrest both in vitro8
and in vivo9–11. However, it is still unclear how Notch exerts its
negative effects on EC proliferation, and the transcriptional
programme that triggers stalk cell function is not
understood2,5,12. Furthermore, it is not clear how stalk cells are
ultimately released from this arrest to provide sufﬁcient cell
numbers for the sprout to elongate and stabilize.
PTEN (phosphate and tensin homologue deleted on
chromosome TEN) is a dual lipid/protein phosphatase, which
is often underexpressed in cancer13–15. The main activity of
PTEN is to dephosphorylate the lipid phosphatidylinositol
3,4,5-trisphosphate (PtdIns(3,4,5)P3) at the 3´-position, thereby
counterbalancing class I phosphoinositide 3-kinase (PI3K)
signalling that mediates growth, cell division, survival,
migration and metabolism13,16–18. Genetic studies in mouse
and zebraﬁsh point to a restrictive role of PTEN in angiogenesis.
Mice lacking PTEN speciﬁcally in ECs exhibit cardiac failure and
severe haemorrhages due to defects of the myocardial wall and
impaired mural cell coverage of blood vessels19. Mutant zebraﬁsh
embryos lacking functional PTEN show enhanced angiogenesis20;
whether this is due to a cell-autonomous effect of PTEN in ECs or
is simply a consequence of increased VEGF levels is unclear.
Importantly, the speciﬁc functions of PTEN in endothelial
behaviour and vascular patterning remain unknown.
In most cells and tissues, PTEN localizes to the cytoplasm and
the nucleus13,15. There is evidence to suggest that PTEN
has nuclear, non-lipid phosphatase-dependent functions21,22.
Interestingly, PTEN localization is cell cycle-dependent, with
higher levels of nuclear PTEN during the G0–G1 phase than
during the S phase23,24. This is in line with the observation that
nuclear PTEN negatively regulates cell cycle progression13,22.
Indeed, in late mitosis and G1, nuclear PTEN enhances the E3
ligase activity of APC/C by facilitating the association of APC/C
with its activator Fzr1/Cdh1 (encoded by the Fzr1 gene), with no
requirement of its phosphatase activity22. The APC/C-Fzr1/Cdh1
complex controls G1 progression by targeting several proteins for
degradation, including mitotic cyclins (Cyclin-A), mitotic kinases
(Aurora Kinase A (Aurora A) and Polo-like kinase 1 (Plk1)),
proteins involved in chromosome segregation and DNA
replication (Geminin; ref. 25). Despite the large body of
molecular evidence, the role and relevance of nuclear PTEN in
physiology is poorly understood.
Here we report that endothelial PTEN regulates stalk cell
proliferation during vessel development. Our data further identify
PTEN as a key mediator of the antiproliferative responses of
Notch. We show that Dll4/Notch signalling arrests stalk cell
proliferation by inducing expression of PTEN to balance stalk cell
numbers and coordinate patterning. On PTEN deletion, Notch
signalling fails to arrest early stalk cells and result in defective
sprout length and patterning. Our results strongly indicate that
both catalytic and non-catalytic activities of PTEN contribute to
this function, providing evidence for an important in vivo
physiological function for the PTEN-APC/C-Fzr1/Cdh1/axis.
Results
PTEN negatively regulates vascular density in angiogenesis.
To study the EC-autonomous role of PTEN in sprouting
angiogenesis, we crossed Ptenﬂox/ﬂox mice with PdgfbiCreERT2
transgenic mice that express a tamoxifen-activatable Cre
recombinase in ECs26 (further referred to as PTENiDEC/iDEC) and
assessed postnatal retinal angiogenesis. 4-hydroxytamoxifen
(4-OHT) was administrated in vivo at postnatal day 1 (P1) and
P2, followed by analysis of the retinal vasculature at different time
points. Comparing whole-mount-stained retinas of control
(Ptenﬂox/ﬂox) to PTENiDEC/iDEC mice at P5 revealed a mild
increase in vessel width (Supplementary Fig. 1a–g). By P7, loss of
PTEN resulted in excessive branching and substantially increased
vessel width (Fig. 1a–d), a phenotype that was further exacerbated
at P10 (Fig. 1h,i). PTENiDEC/iDEC P7 retinas showed efﬁcient
recombination of the Cre-reporter R26-R and depletion of PTEN
in the retinal endothelium (Supplementary Fig. 1h,i), with an
increase in staining for phosphoS6 (pS6), a marker of PI3K
pathway activation (Supplementary Fig. 1j). Isolated mouse lung
ECs (mECs) from PTENiDEC/iDEC mice conﬁrmed that effective
depletion of PTEN protein in mECs was achieved 96 h following
4-OHT administration (Supplementary Fig. 1k,l). To further
characterize the cell-autonomous role of PTEN in ECs, we
therefore focused on the P7 time point. No differences in radial
expansion (Fig. 1e) and in the number of sprouts per 100mm of
leading endothelial membrane were found in PTENiDEC/iDEC
when compared with control retinas (Fig. 1f). Instead, the length
of the sprouts was signiﬁcantly reduced in the PTENiDEC/iDEC
retinal vasculature compared with controls (Fig. 1g). The
hyperplastic phenotype observed on PTEN loss was validated in
an independent cellular system based on embryoid body (EB)
formation, in which clusters of embryonic stem cells respond to
VEGF by forming vascular tubes27. Compared with wild type
(WT), PTEN null EBs showed increased sprout width and length
(Supplementary Fig. 2a–d), with no differences in the number of
sprouts (Supplementary Fig. 2e).
Next, we sought to address whether regulated elevation in
PTEN expression in vivo would oppose the phenotype induced by
loss of PTEN. To this end, we used super-PTEN transgenic mice
(PTENTG)28, a mouse model that allows moderate organismal
elevation of PTEN levels (two-fold over WT littermates),
including in the vasculature (Supplementary Fig. 1m). PTENTG
retinas exhibited decreased vessel width and increased sprout
length (Fig. 1j,k,m,p), with no changes in the number of branches
(Fig. 1l) and sprouts (Fig. 1o). A slight reduction in radial
expansion was also observed on moderate PTEN overexpression
(Fig. 1n), similar to retinas from mice that are heterozygous for a
kinase-dead p110a PI3K allele29. Neither loss nor gain of PTEN
function resulted in changes in Dll4 or Notch target genes
(Supplementary Fig. 3a–c), further supporting that PTEN is not
required for tip/stalk selection. Analysis of EphB4, EphrinB2 and
Nr2f2 gene expression, key genes involved in arteriovenous
differentiation, did also not reveal any obvious difference between
control and loss and gain of PTEN function in ECs, suggesting
that PTEN signalling does not play a predominant role in this
process (Supplementary Fig. 3d,e).
Taken together, these data uncover a selective role for PTEN in
angiogenesis, regulating vascular density and consequently vessel
growth in vivo.
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PTEN regulates endothelial stalk cell number. Previous data
have shown that constitutive targeting of PTEN in ECs results in
altered mural cell coverage19. Instead, immunostaining with
desmin, a retinal pericyte marker30, did not reveal any obvious
defect in mural cell coverage in PTENiDEC/iDEC retinas compared
with control, consistent with the lack of sprouting defects on
PTEN loss (Supplementary Fig. 3f).
Analysis of PTENiDEC/iDEC retinas stained with a nuclear
endothelial marker (Erg) revealed increased EC numbers in the
angiogenic vasculature (Fig. 2a,b). Conversely, elevated PTEN
expression resulted in reduced EC numbers at the sprouting front
(Fig. 2c,d). We sought to validate whether these differences relate
to changes in EC proliferation. Surprisingly, no difference in the
number of proliferative ECs located in the subfront retinal area,
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Figure 1 | PTEN regulates vascular density. (a,b) Whole-mount visualization of blood vessels by isolectin B4 (IB4) staining of control and PTENiDEC/iDEC
littermates at P7. (c–g) Quantitative analysis of the retinas shown in a,b. (c) Vascular branch points per unit area (nZ6). (d) Vessel width (nZ4). (e)
Radial expansion of blood vessels (nZ7). (f) Number of sprouts per vascular front length (nZ7). (g) Sprout length from the tip to the base of the sprout
(nZ7). (h,i) Whole-mount visualization of blood vessels by IB4 staining of control and PTENiDEC/iDEC littermates at P10. (j,k) Whole-mount visualization of
blood vessels by IB4 staining of WTand PTENTG littermates at P7. (l–p) Quantitative analysis of the retinas shown in j,k. (l) Vascular branch points per unit
area (n¼ 8). (m) Vessel width (n¼ 12). (n) Radial expansion of blood vessels (n¼4). (o) Number of sprouts per vascular front length (n¼ 6). (p) Sprout
length from the tip to the base of the sprout (n¼6). Scale bars, 100mm (a,h,j) and 20mm (b,i,k). Error bars are s.e.m. *Po0.05, **Po0.01 and ***Po0.001
were considered statistically signiﬁcant. Statistical analysis was performed by nonparametric Mann–Whitney test.
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Figure 2 | PTEN negatively regulates stalk cell proliferation. (a) IB4 (blue) and Erg (red) staining of control and PTENiDEC/iDEC littermate retinas at P7.
Islets show higher magniﬁcation of selected regions shown to the right. (b) Quantiﬁcation of EC nuclei per unit area assessed by Erg positivity in control
and PTENiDEC/iDEC P7 retinas (nZ4). (c) IB4 (blue) and Erg (red) staining of WT and PTENTG littermate retinas at P7. Islets show higher magniﬁcation
of selected regions shown to the right. (d) Quantiﬁcation of EC nuclei per unit area assessed by Erg positivity in WT and PTENTG P7 retinas (n¼ 8).
(e) IB4 (blue), Erg (red) and Edu (green) staining of control and PTENiDEC/iDEC P7 retinas. Islets show higher magniﬁcation of selected regions shown
below. Arrows indicate Edu-positive ECs in the sprouting front. (f) Quantiﬁcation of Edu-positive cells per unit area assessed in control and PTENiDEC/iDEC
P7 retinas (nZ7). (g) Quantiﬁcation of number of Edu-positive cells located at the sprouting front expressed per vascular front length in control and
PTENiDEC/iDEC P7 retinas (n¼ 7). (h) IB4 (blue), Erg (red) and Edu (green) staining of WT and PTENTG littermate retinas at P7. Islets show higher
magniﬁcation of selected regions shown below. Arrows indicate Edu-positive ECs in the sprouting front. (i) Quantiﬁcation of Edu-positive cells per unit area
assessed in WTand PTENTG P7 retinas (n¼4). (j) Quantiﬁcation of number of Edu-positive cells located at the sprouting front expressed per vascular front
length in WTand PTENTG retinas (n¼4). Scale bars, 20mm (a,c,e,h). Error bars are s.e.m. *Po0.05 and **Po0.01 were considered statistically signiﬁcant.
Statistical analysis was performed by nonparametric Mann–Whitney test.
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behind the sprouting front, was found on either loss (Fig. 2e,f) or
gain of PTEN function (Fig. 2h,i). This is unexpected, given that
in the growing vasculature ECs with high turnover are located in
this subfront area (Supplementary Fig. 4a,b). To test whether
PTEN regulated proliferation of ECs in other retinal locations,
we focused on the ﬁrst line of cells located at the sprouting front
where proliferating cells are rarely observed (Supplementary
Fig. 4a,b). Interestingly, a 40% increase in proliferation in
PTENiDEC/iDEC retinas (Fig. 2g) or 60% reduction in PTENTG
retinas (Fig. 2j) compared with control retinas was observed in
ECs at the front. These data point towards a selective role of
PTEN in restricting EC proliferation in cells located at the
sprouting front.
PTEN executes Notch-dependent cell cycle arrest. Given
that the impact of PTEN loss or overexpression in vivo on
proliferation are restricted to the sprouting front that is highly
Notch-dependent9, we hypothesized that a functional connection
exists between these two signalling pathways. Activation of
Notch in mECs, both in vivo and in vitro, resulted in cell cycle
arrest, shown by reduced 5-bromo-2’-deoxyuridine (BrdU)
incorporation (Supplementary Fig. 4c,d and Fig. 3a) and
downregulation of cell cycle regulators including Cyclin D and
A, Plk1, Aurora A and Geminin (Fig. 3b). Interestingly, genetic
manipulation of PTEN levels in ECs altered the antiproliferative
response to Notch activation (Fig. 3c,e). PTENiDEC/iDEC mECs
failed to stop proliferation on Notch activation (Fig. 3c,d),
whereas PTENTG mECs showed a 50% increase in the cell cycle
arrest response (Fig. 3e,f). Consistent with a role of PTEN in
regulating the cell cycle arrest, higher PTEN levels in ECs in vivo
corresponded to nonproliferative cells (Supplementary Fig. 4e,f).
Our results suggest that PTEN is necessary for the growth-
suppressive activity of Notch signalling in ECs and imply that the
PTEN loss-of-function phenotype is the result of an impaired
response to Dll4 stimulation.
Because PTEN is required for the Notch-dependent regulation
of endothelial proliferation, we tested whether PTEN expression
is regulated by Notch. Bioinformatic analysis of the PTEN locus
identiﬁed the presence of three Rbpj motifs that are conserved in
both the human and mouse PTEN gene (Fig. 3g). We used
chromatin immunoprecipitation (ChiP) analysis on human ECs
to determine the recruitment of NICD protein to the PTEN
promoter after 2 h of incubation with Dll4. PTEN promoter
occupancy was determined using real-time quantitative PCR
(qPCR) probes that amplify seven regions spanning from  2,380
to  590 relative to the transcription initiation site. Our analysis
revealed NICD occupancy in the  1,492 region, which contains
one of the three predicted Rbpj-binding sites (Fig. 3g). We next
validated the functional signiﬁcance of Rbpj binding to the
promoter in luciferase reporter assays. Indeed, analysis of PTEN
promoter activity showed activation in response to Dll4 (Fig. 3h)
and on overexpression of the intracellular domain of the Notch
receptor (NICD; Fig. 3i). Importantly, enhanced PTEN promoter
responsiveness to Dll4 was abrogated by the g-secretase inhibitor
dibenzazepine (DBZ; Fig. 3i). Western blot experiments con-
ﬁrmed that Dll4 stimulation results in elevated protein levels of
PTEN in human ECs and mECs (Fig. 3j,k). Using lungs as highly
vascularized tissue, we validated that overactivation of Notch
signalling by inhibiting the Notch ligand, Jagged 1 (Jag1)11,
resulted in higher PTEN expression levels (Fig. 3l). Taken together,
these results demonstrate that PTEN is a target gene of Notch
signalling in ECs, which becomes induced by Dll4 stimulation.
PTEN is required for Notch function in vivo. We sought to
conﬁrm the Notch/PTEN functional interaction in vivo. We took
advantage of endothelial Jag1 inactivation, which results in
reduced EC proliferation and decreased vascular branching due to
overactivation of Notch signalling11. We hypothesized that,
if the regulation of the angiogenic process by Notch requires
the increase in PTEN function, loss of PTEN would prevent
the phenotype of Jag1 deletion. We tested this hypothesis in
inducible endothelial-cell-speciﬁc PTENiDEC/iDEC;Jag1iDEC/iDEC
double mutants. The vasculature of Jag1iDEC/iDEC retinas
showed reduced endothelial proliferation and reduced vessel
width, conﬁrming previous reports (Fig. 4a–g and Supplementary
Fig. 5a)11. However, concomitant PTEN deletion abrogated the
phenotype observed in Jag1iDEC/iDEC retinas (Fig. 4a–g), while the
phenotype of PTEN loss remained unaffected by Jag1 deletion
(the increase in endothelial proliferation at the spouting front).
Next, we validated our hypothesis in the PTENTG mice by
blocking Notch activation with the g-secretase inhibitor DAPT
(N-[N-(3,5-diﬂuorophenacetly)-L-alanyl]-S-phenylglycine t-butyl
ester) that strongly enhances angiogenesis partially due to
increased EC proliferation9. Remarkably, DAPT-induced
increase in vascular density at the angiogenic front was
abolished by increased levels of PTEN (Fig. 4h,j,m,n and
Supplementary Fig. 5b). However, elevated levels of PTEN did
not prevent the enhanced sprouting caused by DAPT (Fig. 4i,k,l),
further indicating that PTEN is not required for Notch-
dependent tip/stalk selection.
Dual function of PTEN in angiogenesis. To gain insight into the
biological mechanism underlying the role of PTEN in sprouting
angiogenesis, we investigated the contribution of phosphatase-
dependent and -independent activities of PTEN at the organismal
and cellular levels. We observed a compartmentalization of PTEN
in the nucleus and cytoplasm in cultured control cells (Fig. 5a),
whereas PTENiDEC/iDEC mECs showed no nuclear staining with
some residual positivity in the cytoplasm. PTEN depletion
in mECs resulted in increased Akt phosphorylation and in
accumulation of the E3 ubiquitin ligase APC/C-Fzr1/Cdh1
complex substrates Aurora A, Plk1 and Geminin (Fig. 5b).
Control mECs treated with 4-OHT did not show any of the
aforementioned changes (Fig. 5c). In contrast, mECs isolated
from PTENTG lungs showed reduced Akt phosphorylation and
reduced accumulation of E3 ubiquitin ligase APC/C-Fzr1/Cdh1
complex substrates compared with WT cells (Fig. 5d).
To investigate whether increased levels of the APC/C-Fzr1/
Cdh1 targets were only a consequence of increased PI3K activity,
we tested the impact of GDC-0941 (a pan-class I PI3K inhibitor
that blocks p110a, p110b, p110d and p110g; ref. 31). While
pretreatment with GDC-0941 abrogated Akt activation in
PTENiDEC/iDEC mECs (Fig. 5e), it did not modify the levels of
Aurora A and Geminin (Fig. 5e), further corroborating that the
function of PTEN promoting the APC/C-Fzr1/Cdh1 activity is
independent of its ability to inhibit PI3K signalling through its
lipid phosphatase activity22.
As our data indicate that the principal function of PTEN in
sprouting angiogenesis is to regulate EC proliferation, we tested
to what extent phosphatase-dependent and -independent
activities of PTEN participate in this regulation. In vitro
isolated PTENiDEC/iDEC and PTENTG mECs showed increased
and decreased BrdU incorporation, respectively (Fig. 5f and
Supplementary Fig. 6a,b). Inhibition of PI3K activity and Aurora
kinase, one of the main targets of APC/C-Fzr1/Cdh1 (ref. 22),
partially rescued normal proliferation rate in PTENiDEC/iDEC
mECs (Fig. 5f and Supplementary Fig. 6a). A synergistic effect
was observed on pretreatment with both GDC-0941 and VX680,
further implying a dual function of PTEN in this process.
Next, we complemented PTEN-depleted ECs with either WT
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8935 ARTICLE
NATURE COMMUNICATIONS | 6:7935 | DOI: 10.1038/ncomms8935 | www.nature.com/naturecommunications 5
& 2015 Macmillan Publishers Limited. All rights reserved.
aDll4:
30
0
10
mECs
20
*
Dll4:
60
0
20
40
*
ns
Vehicle 4-OHT
PTEN
Aurora A
β-Actin
b
c d
Plk1
Cyclin A
Cyclin D1
Aurora A
Geminin
Tubulin
Plk1
Cyclin D1
20
0
10
*
HUVECs p27
Cyclin A
Cyclin D1
Aurora A
Geminin
Tubulin
mECs HUVECs
Vehicle 4-OHT
Geminin
1 0.3 1.2 0.9
1 0.3 1.1 1.3
1 0.4 1.4 1.1
1 0.7 1.3 0.7
f
0
PTENTG
PT
EN
TG
PT
EN
TG
25
50
e
**
*
**
WT
WT WT
PTEN
Aurora A
Geminin
Plk1
β-Actin
0
1
2
Dll4:
DBZ:
V5-NICD:
0
1
2
Fo
ld
 a
ct
iva
tio
n
Fo
ld
 a
ct
iva
tio
n

TIS
–
11
32
–
14
92
–
19
14
Rbpj 100 bp
5 6 74321
1 2 3 4 5 6 7
0
2
4
6
8
Fo
ld
 in
cr
ea
se
 v
er
su
s 
in
pu
ts
g h i
**
* *
**
k
PTEN
β-Actin
HUVECs
PTEN
β-actin
8
mECsj
PdgfbiCreERT2: PTENflox/flox 
PdgfbiCreERT2: PTENflox/flox 
1 0.55 0.3 0.17
1 1 1 0.3
1 0.8 0.56 0.49
Br
dU
+
 
EC
s 
pe
r t
ot
al
EC
s 
(%
)
Br
dU
+
 
EC
s 
pe
r t
ot
al
EC
s 
(%
)
Ki
67
+
 
EC
s 
pe
r t
ot
al
 E
Cs
 (%
)
Ki
67
+
 
EC
s 
pe
r t
ot
al
 E
Cs
 (%
)
50
37
50
50
50
25
37
37
50
50
50
50
25
50
50
37
25
37
50
50
37
50
75
37
37
50
Dll4(kDa) Dll4(kDa)
Dll4(kDa) Dll4(kDa)
Dll4
Time (h)  
(kDa)
Dll4
Time (h)  
(kDa)
50
l
PTEN
β-Actin
Hes1
Control Jag1iΔEC/iΔEC
37
37
50
(kDa)
0.96 1 1 0.6 0.8 1.6 0.9 1.4 1.3 1.9 1.8 1.8 1.2
Jag1iΔEC/iΔEC
PT
EN
 e
xp
re
ss
io
n
(no
rm
ali
ze
d b
y β
-
ct
in
)
2
1
0
**
Control
+–
+– +–
+– +–
Dll4: +–
+– +–
Dll4: +–
++– –
+–
2424 8
8 2424 8
++– –
+
+
++
+
–
–
– –
–
++– –
Figure 3 | Notch limits EC proliferation by upregulating PTEN levels. (a) Quantiﬁcation of in vitro proliferation of mECs and HUVECs plated for 24 h in
vehicle or Dll4-coated dishes, pulsed with BrdU for 2 h and subjected to immunostaining analysis. At least 100 cells per condition were counted (n¼4).
(b) Immunoblot analysis of mECs and HUVECs plated for 24 h in vehicle or Dll4-coated plates using the indicated antibodies (n¼ 3). Molecular weight
marker (kDa) is indicated. (c,e) Quantiﬁcation of in vitro proliferation by Ki67 immunoﬂuorescence of control and PTENiDEC/iDEC (c) and WTand PTENTG
mEC (e) plated for 24 h in vehicle or Dll4-coated plates. Overall 100 cells per condition were counted (n¼4). (d) Control and PTENiDEC/iDEC or (f) WTand
PTENTG mEC were plated for 24 h in vehicle or Dll4-coated dishes, followed by immunoblot analysis using the indicated antibodies. The quantiﬁcation of
the relative immunoreactivity of each protein normalized to b-actin is represented as the mean of four different experiments in d,f. Molecular weight marker
(kDa) is indicated. (g) ChIP with the anti-NICD antibody from HUVECs and the analysis of the PTEN locus by qPCR. A pool of two independent
experiments is shown. (h,i) PTEN-luciferase reporter assays were performed in HUVECs with a 2,666-bp PTEN promoter construct (pGL3 PTEN
Hind III-NotI). (h) Cells were plated for 6 h in vehicle or Dll4-coated dishes and (i) HUVECs were transfected with V5-NICD (n¼ 3). (j,k) Immunoblot
analysis of PTEN in lung mECs (j) and in HUVECs (k) plated for 8 or 24 h in vehicle or Dll4-coated plates (n¼4). Molecular weight marker (kDa) is
indicated. (l) Immunoblot analysis of PTEN and Hes in lung lysates from control (n¼ 7) and Jag1iDEC/iDEC (n¼6) pups. Molecular weight marker (kDa) is
indicated. Error bars are s.e.m. *Po0.05 and **Po0.01 were considered statistically signiﬁcant. ns, not statistically signiﬁcant. Statistical analysis was
performed by nonparametric Mann–Whitney test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8935
6 NATURE COMMUNICATIONS | 6:7935 |DOI: 10.1038/ncomms8935 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
(PTENWT), phosphatase-inactive (C124S; PTENC124S; refs 32,33)
or nuclear-excluded (K13,289E; PTENK13,289E) PTEN (ref. 22).
Expression of PTENWT, PTENC124S and PTENK13,289E abrogated
the increase in EC proliferation (Fig. 5g and Supplementary
Fig. 6c) of PTEN null ECs, albeit most prominently seen with
PTENWT. All together, these data indicate that phosphatase-
dependent and -independent activities of PTEN are important to
regulate EC proliferation.
Next, we tested the differential contribution of each of these
functions in vivo, by ﬁrst analysing the retinas of PTENiDEC/iDEC
on inhibition of class I PI3K activity with GDC-0941. The
hyperplasia induced by PTEN loss was rescued by inhibiting
PtdIns(3,4,5)P3 production (Fig. 6a–d and Supplementary
Fig. 7a), indicating, as expected, an important role of PTEN
lipid phosphatase activity in vascular growth. Next, we assessed
the contribution of phosphatase-independent activity of PTEN to
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sprouting angiogenesis by inhibiting Aurora kinase. Strikingly,
the phenotype of PTENiDEC/iDEC was abrogated by Aurora kinase
inhibition (Fig. 6e–h), which is consistent with the contribution
of the phosphatase-independent activity of PTEN to sprouting
angiogenesis in vivo. This was further corroborated by genetic
conditional and inducible deletion of Fzr1 in ECs. Complete
depletion of Fzr1/Cdh1 protein was achieved 48 h post incubation
with 4-OHT (Supplementary Fig. 7b,c). Therefore, pups were
treated with 4-OHT at P5 and P6, followed by analysis of the
retinal vasculature at P7. The retinas of Fzr1iDEC/iDEC showed
increased vascular density and reduced length of sprouts
(Fig. 6i–n) comparable to PTENiDEC/iDEC. All together, these
data suggest that, in ECs, there is a dual contribution of PTEN,
counterbalancing the PI3K signalling pathway through its lipid
phosphatase activity and facilitating the APC/C-Fzr1/Cdh1
complex activity, which has been reported to be independent of
its catalytic function22.
Discussion
Here we report that PTEN in ECs is required in a cell-
autonomous and dose-dependent manner for the control of
vascular density and vessel growth, but is dispensable for the
regulation of the sprouting activity of tip cells. We show that
endothelial PTEN restricts vascular growth by limiting stalk cell
proliferation during sprouting angiogenesis. An important
conclusion from this study is that PTEN is not required in all
ECs to regulate proliferation in vivo, as shown in cultured ECs
(our data and ref. 19). Instead, our results indicate that the
consequence of PTEN loss or overexpression in vivo is restricted
speciﬁcally to the zone of the vasculature that is highly
Notch-dependent.
Constitutive targeting of PTEN in ECs leads to embryonic
lethality due to aberrant angiogenesis19. Although these studies
have established that PTEN regulates EC proliferation, the
analysis of vasculature in Tie2Cre-PTENﬂox/ﬂox embryos did
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not allow unravelling precisely how PTEN regulates sprouting
angiogenesis. Furthermore, Hamada et al. were unclear of
whether the aberrant vasculature, which results on PTEN loss,
was a consequence of aberrant PTEN signalling in ECs or simply
a consequence of an altered pro-angiogenic cytokine proﬁle19.
Similarly, zebraﬁsh studies have shown that loss of PTEN leads to
increased VEGF levels and in turn vessel hyperplasia, highlighting
indeed that PTEN also regulates angiogenesis in a paracrine
manner20. Another difference between Hamada et al. and our
study is that constitutive loss of PTEN in ECs also results in
altered mural cell coverage, while induced loss of postnatal
endothelial PTEN does not. These discrepancies suggest that
PTEN may differently regulate angiogenesis in different
vascular beds.
Activation of Notch leads to cell cycle arrest8–11,34. In this
study, we identify PTEN as a critical mediator of Notch
antiproliferative response in stalk cells. If PTEN is not
expressed in ECs, stalk cells become insensitive to the
antiproliferative signals of Notch and exhibit unrestricted
expansion, hence perturbing sprout length and pattern and
eventually resulting in profound hyperplasia. Interestingly, our
results also reveal that stalk cells located further away from the
a
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front are insensitive to changes in PTEN expression. Given that
these stalk cells at the subfront area are highly proliferative, our
data support the existence of two biological states for stalk cells.
A ﬁrst state in which stalk cells must remain arrested to ensure
the correct patterning of the sprout, and a second state in which
cells enter the cell cycle to expand the plexus. These two states are
likely the consequence of dynamic changes in Notch signalling,
with high Notch activity in early nonproliferative stalk cells and
low Notch activity in the late proliferative stalk cells. Our data
predict a rise and fall in PTEN levels that will accompany
the early quiescent and late proliferative phases, respectively.
This is supported by the observation that, in WT cultured ECs,
higher PTEN levels are seen 8 h post stimulation with Dll4
compared with 24 h post stimulation. Furthermore, co-staining of
PTEN and 5-ethynyl-20-deoxyuridine (Edu) in the growing
vasculature showed that Edu-negative cells express higher levels
of PTEN than Edu-positive cells, supporting the notion that
PTEN protein levels rise to guarantee cell cycle arrest. Whether
high PTEN cells correspond to high Notch signalling still needs to
be determined. Moya et al. speculated that early and late stalk cell
behaviours might be orchestrated by oscillation in Notch activity.
The authors proposed that Id proteins, members of HLH
proteins, govern these two states by releasing the negative
autoregulatory loop of Hes1 (ref. 35). While our results are
consistent with the idea of two states, they identify PTEN
as the key mediator of early stalk cell function in response
to Notch.
Why and how Notch exerts a unique negative regulation in the
endothelium while driving proliferation in virtually every other
cell type and in cancer has been a mystery5,36. Our data show that
PTEN negatively regulates cell cycle progression in ECs through
conserved pathways. Critically, what our results illustrate is a
novel interaction between Notch and PTEN in ECs. We ﬁnd that
Notch stimulates PTEN transcription in the endothelium,
an effect that is required for Notch-mediated cell cycle
arrest. Interestingly, in cell types where Notch stimulates cell
cycle progression, PTEN is transcriptionally repressed by
Notch/Hes36–38. The PTEN gene locus contains both Rbpj- and
Hes-binding sites, suggesting that binding to one or another is
what determines the ﬁnal biological output.
In line with the observation that PTEN restricts stalk cell
proliferation, endothelial gain and loss of PTEN proliferation
phenotypes are reminiscent of gain and loss of Notch function in
stalk cells9–11. However, in response to Notch signalling PTEN
appears to only regulate EC proliferation while it is not required
for tip and stalk speciﬁcation. This is shown by the observation
that Notch mutants not only show aberrant proliferation
phenotypes in the nascent plexus but also sprouting defects9,11,
while PTEN mutants only show vascular density defects. In the
same line, increased levels of PTEN protect angiogenic ECs
treated with DAPT from uncontrolled proliferation but fail to
prevent excessive tip cell numbers. Conversely, a recent study has
shown that inhibitors of the VEGFR3 kinase activity rescue the
hypersprouting phenotype of Notch loss-of-function mutants,
without reducing EC proliferation39. Taken together, these data
suggest that Notch regulates tip cell numbers and stalk cell
proliferation independently through VEGFR3 and PTEN
pathways, respectively.
The predominant activity of PTEN is the dephosphorylation
of PtdIns(3,4,5)P3 and thus the counteraction of class I
PI3K-mediated functions13,15. However, PTEN also exhibits
PtdIns(3,4,5)P3-independent functions, including protein
phosphatase14 and non-catalytic activities13,15. In this context,
PTEN can be found in the nucleus where it regulates DNA
stability and cell cycle progression22,40. Several reports have
highlighted the relevance of nuclear PTEN in disease22,41–43. To
date, the physiological relevance of nuclear PTEN in vivo remains
elusive. Our results reveal that both lipid phosphatase-dependent
and non-catalytic activities of PTEN regulate stalk cell
proliferation during sprouting angiogenesis. Inhibition of class I
PI3K activity with GDC-0941 or Aurora kinase with VX680
signiﬁcantly abrogates the phenotype observed on PTEN loss.
However, the observation that pretreatment with either GDC-
0941 or VX680 is not able to completely rescue the hyperplasia
phenotype of PTENiDEC/iDEC retinas and cultured ECs indicates
that both types of activities of PTEN are required to drive the
PTEN response in angiogenesis. Furthermore, genetic deletion of
Fzr1 in ECs recapitulates the phenotype observed on endothelial
loss of PTEN, reinforcing the relevance of nuclear PTEN
facilitating the APC/C-Fzr1/Cdh1 function. Taken together, our
study provides in vivo evidence that nuclear PTEN is not only
involved in disease such as cancer or cerebral ischaemia22,41–43
but is also critical to regulate a fundamental physiological process
such as angiogenesis.
PTEN WT
Dll4
DII4
NICD
Notch
PTEN
PTEN
PTEN
Fzr1/Cdh1
APC/C
APC/C-Fzr1/Cdh1
activity
PIP3
Cell cycle arrest
Tip cell
signal-emitting cell 
Notch signalling 
Stalk cell
signal-receiving cell 
Notch signalling APC/C-Fzr1/Cdh1activity
a b
Dll4
DII4
PTEN NULL
NICD
Notch
Fzr1/Cdh1
APC/C
PTEN
PIP3
Cell proliferation
PTEN
Figure 7 | Schematic model of the role of PTEN in Dll4/Notch-mediated stalk cell cycle arrest. (a) Activation of Notch by Dll4 induces expression of
PTEN, which through its lipid phosphates activity and its nuclear function as a scaffold of the APC/C-Fzr1/Cdh1 blocks stalk cell proliferation. (b) On PTEN
loss, Notch signalling fails to arrest stalk cells and result in defective sprout length and patterning.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8935
10 NATURE COMMUNICATIONS | 6:7935 |DOI: 10.1038/ncomms8935 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
We and others have previously shown that inhibition of class I
PI3K isoform in vivo does not lead to blockade of EC
proliferation29,44–46. Although contradictory, these observations
may reﬂect that PTEN principally regulates EC proliferation
independently of its lipid phosphatase activity22. In line with this,
our data also reveal that the regulation of APC/C-Fzr1/Cdh1 by
PTEN seems to play a major role in response to Notch signalling
in angiogenesis. This is shown by the altered APC/C-Fzr1/Cdh1
target expression under conditions of PTEN loss and Notch
activation. This observation, together with the fact that Notch
stimulation in ECs results in phosphorylation of Akt47,48, suggest
that Notch stimulates PTEN nuclear translocation. These ﬁndings
would be in agreement with the notion that higher nuclear PTEN
levels are found during G0–G1 phase than during the S
phase23,24. Further experiments are needed to elucidate how
PTEN accumulates in the nucleus on Notch activation.
The unique direction of the coupling of Notch and PTEN in
the endothelium (Fig. 7), and the highly selective effects on the
active vascular front raise the prospect that targeting this
interaction and stimulation of PTEN signalling may be used
therapeutically to render EC quiescence in aberrant tumour
angiogenesis and in turn promote a normalization effect.
Clinically, our results imply that stimulating both arms of PTEN
function in ECs could render a more quiescence phenotype of
highly proliferative tumour ECs2,49. However, inhibition of PI3K
in the tumour stroma not only results in reduced EC proliferation
but also in reduced vascular function47. It is thus tempting to
speculate that promoting nuclear PTEN may offer more
selectivity towards a tight control of EC proliferation.
Methods
Reagents. Sources and catalogue numbers of antibodies were as follows: Cell
Signaling Technology: PTEN (#9559), pS473-Akt (#4060) and pSer240/244-S6
(#2215); BD Pharmingen: p27 (#610242), cyclin-D1 (#556470), BrdU (#347580)
and Aurora A Kinase (#610939); NeoMarkers: Ki67 (#RM-9106-S); Abcam: NICD
(#ab27526), desmin (ab15200) and PTEN (ab32199); Santa Cruz Biotechnology:
VE-cadherin (sc-6458), Geminin (#sc-13015), cyclin-A (#sc-53230), Hes1
(#sc-25392) and Erg (sc-353); Millipore: Plk1 (#06-813) and Fzr1/Cdh1 (#CC43);
Sigma-Aldrich: b-actin (A5441) and a-tubulin (T6074). Isolectin GS-IB4 and
secondary antibodies conjugated to Alexa 488, Alexa 568 and Alexa 633, and
Click-iT EdU Alexa 488 and 647 Imaging Kit were from Molecular Probes. Human
(#1506-D4) and mouse Dll4 (#1389-D4) were from R&D Systems. The GDC-0941
compound was from Chem Express Haoyuan (China). The VX680 (MK-0457)
compound was from Selleckchem (USA). All chemicals, unless otherwise stated,
were from Sigma-Aldrich.
Inducible genetic protocols and pharmacological inhibition in mice. Mice were
kept in individually ventilated cages and cared for according to the guidelines
and legislation of the UK Home Ofﬁce and Catalan Departament d’ Agricultura,
Ramaderia i Pesca, with procedures accepted by the Ethics Committees of
CRUK-London Research Institute and IDIBELL-CEEA.
To delete PTEN in postnatal vessels, we crossed the PTENﬂox mice50 into the
transgenic mice expressing the tamoxifen-inducible recombinase CreERT2 under
the control of the endothelial Pdgfb promoter26. To generate PdgfbiCreERT2;
PTENﬂox/ﬂox and PTENﬂox/ﬂox littermates, PdgfbiCreERT2; PTENﬂox/ﬂox were
interbred with PTENﬂox/ﬂox. Cre activity and gene deletion were induced by
intraperitoneal injection of 25 mg 4-OHT (Sigma, H7904 10mgml 1) in all pups
of the litter at P1 and P2, and retinas were collected at different time points (P5, P7
and P10). Class I PI3K signalling or Aurora kinase was inhibited in half of the pups
by subcutaneous injection at 18:00 pm of P6 and 10:00 am of P7 with 37.5 mg g 1
GDC-0941 (ref. 31) or with 50 mg g 1 VX680, respectively, dissolved in
dimethylsulphoxide (DMSO). Retinas were harvested at 18:00 pm of P7.
Control mice were injected with DMSO only.
PTENTG (ref. 28) was maintained in C57/BL6 background and were fed with a
19% protein-extruded rodent diet (Harlan, 2019) in a 1:1 proportion with normal
diet. Notch signalling was inhibited in half of the pups by subcutaneous injection at
P5 and P6, with 100mg kg 1 DAPT (Calbiochem, #565770) and retinas being
harvested at P7.
PdgfbiCreERT2; Fzr1ﬂox/ﬂox were interbred with Fzr1ﬂox/ﬂox (ref. 51) to generate
PdgfbiCreERT2; Fzr1ﬂox/ﬂox and Fzr1ﬂox/ﬂox littermates. Pups were injected with
25mg 4-OHT (10mgml 1) at P5 and P6 and dissected at P7.
For combined endothelial-cell-speciﬁc loss-of-function of PTEN and Jag1, we
crossed PTENﬂox/ﬂox (ref. 50) with Jagged1ﬂox/ﬂox (ref. 52) and PdgfbiCreERT2
(ref. 26). To generate PdgfbiCreERT2; PTENﬂox/ﬂox; Jag1ﬂox/ﬂox (PTENiDEC/iDEC;
Jag1iDEC/iDEC), PdgfbiCreERT2; PTENﬂox/ﬂox (PTENiDEC/iDEC) and PdgfbiCreERT2;
Jag1ﬂox/ﬂox (Jag1iDEC/iDEC) littermates, two different types of breeding were set up;
PdgfbiCreERT2; PTENﬂox/ﬂox; Jag1ﬂox/ﬂox were interbred with PTENﬂox/ﬂox;
Jag1ﬂox/WT or with PTENﬂox/WT; Jag1ﬂox/ﬂox. Cre activity and gene deletion were
induced by intraperitoneal injection of 25 mg 4-OHT (10mgml 1) in all pups of
the litter, at P1 and P3 and retinas were collected at P7. To assess proliferating ECs,
the pups were injected intraperitoneally with 60 ml of Edu (0.5mg 1ml 1) 2 h
before being killed. Edu was dissolved in a 1:1 ratio DMSO:PBS.
Immunoﬂuorescence. Eyes were ﬁxed in 4% paraformaldehye (PFA) for 2 h at
4 C. For PTEN staining, mice were exsanguinated by transcardiac perfusion of
PBS, followed by perfusion with 4% PFA before dissecting and continuing ﬁxing
the retinas with methanol at  20 C. Samples were rehydrated for 30min at room
temperature (RT). After washing twice in PBS, retinas were permeabilized in PBS
containing 1% bovine serum albumin (BSA) and 0.3% Triton X-100 overnight
(ON) at 4 C, followed by incubation with primary antibodies (PTEN (Abcam;
1:75), pSer240/244-S6 (1:100), Erg (1:200), desmin (1:200), Hes1 (1:50) and Ki67
(1:50) in permeabilization buffer ON at 4 C. The following day, the eyes were
washed three times with PBS containing 0.1% Tween (PBT), one time in Pblec
buffer (1% Triton X-100, 1mM CaCl2, 1mM MgCl2 and 1mM MnCl2 in PBS,
pH 6.8) for 30min and then incubated for 2 h at RT or ON at 4 C in Pblec buffer
containing Alexa-conjugated secondary antibodies (1:200) and IB4 (1:300), washed
three times further with PBT and ﬂat-mounted on microscope glass slides with
Mowiol. For ﬁxed confocal laser scanning microscopy, we use a Leica SP5. Images
were analysed with Image J Software and Adobe Photoshop CS5.
Embryoid bodies. ES cells were cultured and EBs were generated, as previously
described27. Brieﬂy, ES cells were regularly cultured on a layer of irradiated
DR4 mouse embryonic ﬁbroblast in DMEM glutamax (Life Technologies,
#61965-026) in the presence of 20% fetal bovine serum, HEPES (30mM), sodium
pyruvate (1.5mM), monothioglycerol (1.5%) and leukaemia inhibitory factor
(Chemicon#ESG1107, 123 units ml 1). For vascular sprouting assays, cells were
cultured for two passages without feeders, depleted of leukaemia inhibitory factor
and left in suspension as hanging drops. Four days after, the formed EBs were
transferred to a polymerized collagen I gel with the addition of 60 ngml 1 VEGF
(Peprotech). The medium was changed on day 6 and every day thereafter. Overall,
70,000 WT ES cells and 10,000 PTEN / ES cells were plated to generate EB.
PTEN / ES cells were provided in ref. 53.
Isolation and stimulation of mECs. Mouse lungs were digested with Dispase
(Life Technologies, #17105-041; 4 unitsml 1) for 1 h at 37 C, followed by positive
selection with antimouse vascular endothelial-cadherin (Pharmingen, #555289)
antibody coated with magnetic beads (Dynal Biotech, #110-35). Cells were
seeded on a 12-well plate, and were coated with gelatin (0.5%) in DMEM/F12
supplemented with 20% fetal calf serum and EC growth factor (PromoCell,
#C30140). After the ﬁrst passage, the cells were re-puriﬁed with vascular
endothelial-cadherin antibody-coated magnetic beads. Cells were cultured until
passage 6. To induce gene deletion, 4-OHT (5 mM) or vehicle (ethanol) was added
to the cultured medium at P4 for 96 h and the medium was replaced every other
day. For Dll4 stimulation, mouse Dll4 (500 mgml 1) was immobilized by coating
culture dishes for 1 h at RT, followed by seeding mECs for 6, 8 or 24 h. Mouse and
human Dll4 were used accordingly.
In vitro measurement of mEC cell proliferation. Overall, 104 mECs were plated
in a 24-well plate for 48 h; 2 h before the termination of the experiment, BrdU
(10 mM) was added to the medium. For Ki67 staining, cells were plated for 24 h in
Dll4-coated dishes. Cells were ﬁxed in 4% PFA for 10min at RT, permeabilized for
10min with TBS-T (25mM Tris HCl pH 7.4, 150mM NaCl, 0.5% Triton X-100),
blocked with TBS-T containing 2% BSA and incubated with primary antibodies
BrdU (1:100) or Ki67 (1:50) at 4 C ON. The following day, cells were washed three
times with TBS-T and incubated with Alexa-conjugated secondary antibodies for
2 h at RT. DAPI was added in the ﬁnal wash. Specimens were mounted in Mowiol.
Cells were visualized in a Nikon-80I microscope. For pharmacological inhibition of
class I PI3K and Aurora kinase, GDC-0941 (1 mM) and VX680 (0.5 mM) were
added, respectively, on plating.
Plasmids and transfections. pRK5-Myc-PTEN, C124S pEGFP-PTEN-wt and
pEGFP-PTEN-K13,289E expressing human WT, lipid phosphatase-inactive and
nuclear-excluded PTEN mutants, respectively, were provided in ref. 22. All three
PTEN mutants were subcloned with an N-terminal yellow ﬂuorescent protein
into a modiﬁed lentiviral vector TRIPZ. Lentiviral particles were prepared by
transfecting HEK293FT cells with the TRIPZ vector of interest and the packaging
vectors psPAX, VSV-G and pTAT. Viral particles in the supernatant were
concentrated with Lenti-X-concentrator (Clontech). mECs of P2 or P3 from
PdgfbiCreERT2; PTENﬂox/ﬂox were infected with lentivirus expressing WT PTEN,
PTEN (C124S) or PTEN (K13,289E) in the presence of viralplus transduction
enhancer (Applied Biological Material #G698). For infection, mECs were plated at
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a density of 4 104 per well of 12-well plate and infected with virus from 293FT
cells 48 h after transfection. After 48 h post infection, mECs were re-plated and
treated with 4-OHT (5 mM) to induce gene deletion for 72 h. Next, 104 mECs were
plated in 24-well plate for 48 h in the presence of doxycycline (4 mM); 2 h before the
termination of the experiment, BrdU (10 mM) was added to the medium. Cells were
then ﬁxed in 4% PFA for 10min at RT, permeabilized for 10min with TBS-T
(25mM Tris HCl pH 7.4, 150mM NaCl, 0.5% Triton X-100), blocked with TBS-T
containing 2% BSA and incubated with primary antibodies BrdU (1:100) at 4 C
ON. The following day, cells were washed three times with TBS-T and incubated
with Alexa-conjugated secondary antibodies for 2 h at RT. DAPI was added in the
ﬁnal wash. Specimens were mounted in Mowiol. Cells were visualized in a Nikon-
80I microscope.
MTS viability assay. mECs were cultured in 96-well plate (2,000 cells per 100 ml
culture medium per well) in the presence of the test compounds (GDC-0941 (1 mM)
and VX680 (0.5 mM)) or the respective controls for 48 h, followed by MTS assay
(Promega, #G5421).
Protein extraction and immunoblotting. mECs, human umbilical vascular ECs
(HUVECs (Lonza #CC-2519)) and lungs were lysed in 50mM Tris HCl pH 7.4,
5mM EDTA, 150mM NaCl, 50mM NaF and 1% Triton X-100 supplemented with
2mgml 1 aprotinin, 1mM pepstatin, 1 ngml 1 leupeptin, 1mM phenylmethy-
sulfonylﬂuoride and 1mM sodium orthovanadate, followed by clearance of lysates
using microcentrifugation. Supernatants were resolved on a 10% SDS–PAGE gel,
transferred on nitrocellulose membranes and probed with the indicated antibodies.
Detection was performed by enhanced chemiluminescence. Uncropped immuno-
blots and larger blot areas are presented in Supplementary Fig. 8.
qPCR analysis. qPCR was performed using the following proprietary TaqMan
Gene Expression assay FAM/TAMRA primers (Applied Biosystems): Dll4
(Mm00446968_m1), Hes1 (Mm01342805_m1), Hey1 (Mm00468865_m), Nrarp
(Mm00482529_m1), Ephb4 (Mm00438750_m1), Efnb2 (Mm01215897_m1),
Nr2f2 (Mm00772789_m1) and Hprt (Mm00446968_m1). The levels of PTEN
mRNA were measured using SYBR Green I Master (Roche, #04.887.352.001) in the
LightCycler480 system. Primers used are as follow: forward (50-GTTTACCGGCA
GCATCAAAT-30) and reverse (50-CCCCCACTTTAGTGCAC-30).
Luciferase assays. Reporter assays in HUVECs were performed with the Dual
Luciferase Assay System (Promega, #E1910) and a LUMAT LB 9507 luminometer
(BERTHOLD Technologies). HUVECs were grown to 60–70% conﬂuence in
endothelial basal medium (EGM; Lonza #CC-3124) and co-transfected (Trans Pass
V Reagents (New England Biolabs, # M2558S)) with V5-NICD (ref. 54),
PTEN-luciferase reporter (pGL3 PTEN HindIII-NotI) construct37 and the
constitutive Renilla luciferase reporter pGL4.74hRluc/TK (Promega). Twenty-four
hours after, HUVECs were lysed and reporter assays performed according to the
manufacturers’ protocol. To induce Notch activity with Dll4, transfected HUVECs
were re-plated on Dll4-coated dishes 6 h after plasmid infection. Luciferase activity
was measured after an additional 24 h. To inhibit Notch signalling, cells were
pretreated for at least 1 h before stimulating with Dll4 with 0.08 mM DBZ
((S,S)-2-[2-(3,5-Diﬂuorophenly)acetylamino]-N-(5-methyl-6-oxo-6,7-dihydro-
5H-dibenzo[b,d]azepin-7-yl)propionamide).
ChiP assay. To analyse the binding sites for RBPJ located in the PTEN proximal
promoter, we used the Genomatix software. For analysis, the gene bank sequence
used was NG_007466.2, which contains the promoter sequence AF406618.1. Three
putative RBPJ-binding sites located at  1,914,  1,492 and  1,132 positions
relative to transcription initiation site37 were identiﬁed. ChiP assay was performed
as previously described55. Brieﬂy, chromatin was isolated from HUVECs
stimulated for 2 h with vehicle or Dll4 (500 ngml 1). Crosslinked chromatin was
sonicated for 10min, to medium-sized powder particles, at 0.5-min intervals, with
a Bioruptor (Diagenode) and precipitated with anti-NCID or control IgG. After
crosslinkage reversal, DNA was used as a template for PCR. qPCR was performed
with SYBR Green I Master (Roche, #04.887.352.001) in the LIghtCycler480 system.
Primers used are described in Supplementary Table 1.
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